Veracyte, maker of the Decipher Prostate Genomic Classifier, Joins ACRO as Corporate Sponsor

Veracyte and its Decipher team have joined ACRO as a corporate sponsor at the Gold Level. 

The Decipher Prostate Genomic Classifier provides meaningful and independent data to assess the underlying biology and risk of an individual patient’s prostate cancer. The test has been validated in over 75 studies of more than 60,000 patients as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival.  

• Decipher Prostate Biopsy helps determine if patients are suitable for active surveillance, if they need monotherapy, or if they may benefit from multi-modality or intensified therapy. 
• Decipher Prostate RP helps determine treatment timing following radical prostatectomy and whether patients undergoing salvage radiotherapy may benefit from the addition of ADT.
  

Developed from a large cohort of post-prostatectomy prostate cancer patients treated at the Mayo Clinic, with long-term follow-up, the whole-transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk. When used in conjunction with clinical information, Decipher Prostate provides clarity and confidence in treatment planning.

Decipher Prostate is brought to you by Veracyte (Nasdaq: VCYT), a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the ten most prevalent cancers as defined by incidence in the United States, including prostate cancer.  For more information, please visit http://www.veracyte.com/decipher and follow the company and product pages on Twitter (@Veracyte and @Decipher_VCYT).

ACRO Leadership would like to thank Veracyte and its Decipher team for their partnership.

Click here to learn more.